Characterization of a 3;6 translocation associated with renal cell carcinoma

Genes Chromosomes and Cancer

Volumn 46, Issue 4, 2007, Pages 311-317

  Foster, Rebecca E ^a   Abdulrahman, Mahera ^a   Morris, Mark R ^a   Prigmore, Elena ^b   Gribble, Susan ^b   Ng, Beeling ^b   Gentle, Dean ^a   Ready, Steven ^a   Weston, Phil M T ^c   Wiesener, Michael S ^d   Kishida, Takeshi ^e   Yao, Masahiro ^e   Davison, Val ^f   Barbero, Jose Luis ^g   Chu, Carol ^h   Carter, Nigel P ^b   Latif, Farida ^a   Maher, Eamonn R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

^f BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^g CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^h ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GENETICS; CARCINOGENESIS; CHROMOSOME 3Q; CHROMOSOME 6Q; CHROMOSOME ANALYSIS; CHROMOSOME BREAKAGE; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 3; CONTROLLED STUDY; EPHA7 GENE; EPHB1 GENE; EXON; FIBROBLAST; GENE EXPRESSION; GENE INACTIVATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC LINKAGE; HUMAN; HUMAN CELL; INTRON; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPHOBLAST; NUCLEOTIDE SEQUENCE; PPP2R3A GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNF184 GENE; STAG1 GENE; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; VHL GENE;

CARCINOMA, RENAL CELL; CELL LINE, TRANSFORMED; CHROMOSOMES, HUMAN, PAIR 3; CHROMOSOMES, HUMAN, PAIR 6; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; TRANSLOCATION, GENETIC;

EID: 33947158579     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20403     Document Type: Article

References (45)

1. Atalay A, Crook T, Ozturk M, Yulug IG. 2002. Identification of genes induced by BRCA1 in breast cancer cells. Biochem Biophys Res Commun 299:839-846.
2. Blute ML, Itano NB, Cheville JC, Weaver AL, Lohse CM, Zincke H. 2003. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma. J Urol 169:1276-1281.
3. Bodmer D, Eleveld M, Kater-Baats E, Janssen I, Janssen B, Weterman M, Schoenmakers E, Nickerson M, Linehan M, Zbar B, van Kessel GA. 2002. Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21). Hum Mol Genet 11:641-649.
4. Bodmer D, Eleveld MJ, Ligtenberg MJ, Weterman MA, Janssen BA, Smeets DF, de Wit PE, Van den Berg A, Van den Berg E, Koolen MI, van Kessell GA. 1998. An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am J Hum Genet 62:1475-1483.
5. Bodmer D, Schepens M, Eleveld MJ, Schoenmakers EF, van Kessel GA. 2003. Disruption of a novel gene, DIRC3, and expression of DIRC3-HSPBAP1 fusion transcripts in a case of familial renal cell cancer and t(2;3)(q35;q21). Genes Chromosomes Cancer 38:107-116.
6. Chen J, Lui WO, Vos MD, Clark GJ, Takahashi M, Schoumans J, Khoo SK, Petillo D, Lavery T, Sugimura J, Astuti D, Zhang C, Kagawa S, Maher ER, Larsson C, Alberts AS, Kanayama HO, Teh BT. 2003. The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell 4:405-413.
7. Crolla JA, Van Heyningen V. 2002. Frequent chromosome aberrations revealed by molecular cytogenetic studies in patients with aniridia. Am J Hum Genet 71:1138-1149.
8. Depaepe V, Suarez-Gonzalez N, Dufour A, Passante L, Gorski JA, Jones KR, Ledent C, Vanderhaeghen P. 2005. Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature 435:1244-1250.
9. Druck T, Podolski J, Byrski T, Wyrwicz L, Zajaczek S, Kata G, Borowka A, Lubinski J, Huebner K. 2001. The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. J Hum Genet 46:583-589.
10. Eleveld MJ, Bodmer D, Merkx G, Siepman A, Sprenger SH, Weterman MA, Ligtenberg MJ, Kamp J, Stapper W, Jeuken JW, Smeers D, Smits A, Van Kessel AG. 2001. Molecular analysis of a familial case of renal cell cancer and a t(3;6)(q12;q15). Genes Chromosomes Cancer 31:23-32.
11. Fiegler H, Gribble S, Burford D, Carr P, Prigmore E, Porter K, Clegg S, Crolla J, Dennis N, Jacobs P, Carter NP. 2003. Array painting: A method for the rapid analysis of aberrant chromosomes using DNA microarrays. J Med Genet 40:664-670.
12. Gemmill RM, Bemis LT, Lee JP, Sozen MA, Baron A, Zeng C, Erickson PF, Hooper JE, Drabkin HA. 2002. The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. Oncogene 21:3507-3516.
13. Gemmill RM, West JD, Boldog F, Tanaka N, Robinson LJ, Smith DI, Li F, Drabkin HA. 1998. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc Natl Acad Sci USA 95:9572-9577.
14. Gribble SM, Prigmore E, Burford DC, Porter KM, Ng BL, Douglas EJ, Fiegler H, Carr P, Kalaitzopoulos D, Clegg S, Sandstrom R, Temple IK, Youings SA, Thomas NS, Dennis NR, Jacobs PA, Crolla JA, Carter NR 2005. The complex nature of constitutional de novo apparently balanced translocations in patients presenting with abnormal phenotypes. J Med Genet 42:8-16.
15. Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T. 2004. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem 50:490-499.
16. Han DC, Shen TL, Miao H, Wang B, Guan JL. 2002. EphB1 associates with Grb7 and regulates cell migration. J Biol Chem 277:45655-45661.
17. Hendrix P, Mayer-Jaekel RE, Cron P, Goris J, Hofsteenge J, Merlevede W, Hemmings BA. 1993. Structure and expression of a 72-kDa regulatory subunit of protein phosphatase 2A: Evidence for different size forms produced by alternative splicing. J Biol Chem 268:15267-15276.
18. Huynh-Do U, Vindis C, Liu H, Cerretti DP, McGrew JT, Enriquez M, Chen J, Daniel TO. 2002. Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J Cell Sci 115:3073-3081.
19. Janssens V, Goris J, Van Hoof C. 2005. PP2A: The expected tumor suppressor. Curr Opin Genet Dev 15:34-41.
20. Kanayama H, Lui WO, Takahashi M, Naroda T, Kedra D, Wong FK, Kuroki Y, Nakahori Y, Larsson C, Kagawa S, Teh BT. 2001. Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma. J Med Genet 38:165-170.
21. Kemp Z, Carvajal-Carmona L, Spain S, Barclay E, Gorman M, Martin L, Jaeger E, Brooks N, Bishop DT, Thomas H, Tomlinson I, Papaemmanuil E, Webb E, Sellick GS, Wood W, Evans G, Lucassen A, Maher ER, Houlston RS. 2006. Evidence for a colorectal cancer susceptibility locus on chromosome 3q21-q24 from a high-density SNP genome-wide linkage scan. Hum Mol Genet 15:2903-2910.
22. Kim ST, Xu B, Kastan MB. 2002. Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. Genes Dev 16:560-570.
23. Kim WY, Kaelin WG. 2004. Role of VHL gene mutation in human cancer. J Clin Oncol 22:4991-5004.
24. Kovacs G, Brusa P, De Riese W. 1989. Tissue-specific expression of a constitutional 3;6 translocation: Development of multiple bilateral renal-cell carcinomas. Int J Cancer 43:422-427.
25. Lara-Pezzi E, Pezzi N, Prieto I, Barthelemy I, Carreiro C, Martinez A, Maldonado-Rodriguez A, Lopez-Cabrera M, Barbero JL. 2004. Evidence of a transcriptional co-activator function of cohesin STAG/SA/Scc3. J Biol Chem 279:6553-6559.
26. Maher ER. 2004. Von Hippel-Lindau disease. Curr Mol Med 4:833-842.
27. Mandriota SJ, Turner KJ, Davies DR, Murray PG, Morgan NV, Sowter HM, Wykoff CC, Maher ER, Harris AL, Ratcliffe PJ. 2002. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1:459-468.
28. Maxwell PH, Wiesener MS, Chang GTW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliff PJ. 1999. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
29. Melendez B, Rodriguez-Perales S, Martinez-Delgado B, Otero I, Robledo M, Martinez-Ramirez A, Ruiz-Llorente S, Urioste M, Cigudosa J, Benitez J. 2003. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1). Hum Genet 112:178-185.
30. Morris MR, Hesson LB, Wagner KJ, Morgan NV, Astuti D, Lees RD, Cooper WN, Lee J, Gentle D, Macdonald F. 2003. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 22:6794-6801.
31. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K. 1996. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597.
32. Pekarsky Y, Palamarchuk A, Huebner K, Croce CM. 2002. FHIT as tumor suppressor: Mechanisms and therapeutic opportunities. Cancer Biol Ther 1:232-236.
33. Rodriguez-Perales S, Melendez B, Gribble SM, Valle L, Carter NP, Santamaria I, Conde L, Urioste M, Benitez J, Cigudosa JC. 2004. Cloning of a new familial t(3;8) translocation associated with conventional renal cell carcinoma reveals a 5 kb microdeletion and no gene involved in the rearrangement. Hum Mol Genet 13:983-990.
34. Schmidt L, Li F, Brown RS, Berg S, Chen F, Wei MH, Tory K, Lerman MI, Zbar B. 1995. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J Sci Am 1:191.
35. Severin MD, Leong T 2001. Novel DNA sequence variants in the hHR21 DNA repair gene in radiosensitive cancer patients. Int J Radiat Oncol Biol Phys 50:1323-1331.
36. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. 2003. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425:307-311.
37. Subramonian K, Weston PM, Curley P. 1998. Multifocal renal cancer associated with renal artery aneurysm and a unique genetic change. Br J Urol 82:761-762.
38. Surawska H, Ma PC, Salgia R. 2004. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev 15:419-433.
39. Teh BT, Giraud S, Sari NF, Hii SI, Bergerat JP, Larsson C, Limacher JM, Nicol D. 1997. Familial non-VHL non-papillary clear-cell renal cancer. Lancet 349:848-849.
40. Uhlmann F. 2004. The mechanism of sister chromatid cohesion. Exp Cell Res 296:80-85.
41. Valle L, Cascon A, Melchor L, Otero I, Rodriguez-Perales S, Sanchez L, Cruz Cigudosa J, Robledo M, Weber B, Urioste M. 2005. About the origin and development of hereditary conventional renal cell carcinoma in a four-generation t(3;8)(p14.1;q24.23) family. Eur J Hum Genet 13:570-578.
42. Velagaleti GV, Bien-Willner GA, Northup JK, Lockhart LH, Hawkins JC, Jalal SM, Withers M, Lupski JR, Stankiewicz P. 2005. Position effects due to chromosome breakpoints that map approximately 900 Kb upstream and approximately 1.3 Mb downstream of SOX9 in two patients with campomelic dysplasia. Am J Hum Genet 76:652-662.
43. Woodward ER, Clifford SC, Astuti D, Affara NA, Maher ER. 2000. Familial clear cell renal cell carcinoma (FCRC): Clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 37:348-353.
44. Yazdi PT, Wang Y, Zhao S, Patel N, Lee EY, Qin J. 2002. SMC1 is a downstream effector in the ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev 16:571-582.
45. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Lauf F, Maher ER. 2002. Identification of cyclin D1 (CCND1) and other novel targets for the VHL tumour suppressor gene by expression array analysis and investigation of CCND1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62:3803-3811.